J&J's Janssen Seeks Europe OK For Subcutaneous Darzalex in Multiple Myeloma
July 19 2019 - 7:45AM
Dow Jones News
By Colin Kellaher
Johnson & Johnson's (JNJ) Janssen Pharmaceutical Cos. unit
on Friday said is seeking approval from the European Medicines
Agency for subcutaneous use of Darzalex in patients with multiple
myeloma.
Darzalex is currently only approved for intravenous use.
Janssen said subcutaneous Darzalex is co-formulated with
Halozyme Therapeutics Inc.'s (HALO) Enhanze drug-delivery
technology.
Janssen last week filed for U.S. Food and Drug Administration
approval for the subcutaneous formulation of Darzalex in multiple
myeloma, a cancer that forms in a type of white blood cells called
plasma cells and causes cancer cells to accumulate in the bone
marrow.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
July 19, 2019 07:30 ET (11:30 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Aug 2024 to Sep 2024
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Sep 2023 to Sep 2024